PT  - JOURNAL ARTICLE
AU  - Alexey Rumyantsev
AU  - Alexandra Tyulyandina
AU  - Mikhail Fedyanin
AU  - Ilya Pokataev
AU  - Elena Glazkova
AU  - Sergey Tjulandin
TI  - Platinum vs non-platinum chemotherapy for platinum-resistant ovarian cancer: a systematic review and meta-analysis
AID  - 10.1101/2022.07.12.22277568
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.12.22277568
4099  - http://medrxiv.org/content/early/2022/07/15/2022.07.12.22277568.short
4100  - http://medrxiv.org/content/early/2022/07/15/2022.07.12.22277568.full
AB  - Background recurrent ovarian cancer (OC) patients with platinum-free interval (PFI) <6 mo. are usually considered platinum-resistant and treated with non-platinum based chemotherapy. However, this was never confirmed in proper-conducted randomized trials.Methods we queried the PubMed database for all full-text articles and abstracts on the treatment of patients with platinum-resistant ovarian cancer (PROC) in 01/01/2000-01/06/2019 timeframe. The PRISMA tool was used to ensure transparent reporting of the results. Inclusion criteria were: 1) morphologically confirmed epithelial ovarian cancer; 2) recurrent disease within 6 months after completion of platinum-based chemotherapy; 3) treatment with platinum- or non-platinum chemotherapy with agents that are routinely used for OC; 4) no concomitant therapy with targeted or investigational agents or non-platinum doublets; 5) defined response rate (RR) and assessment criteria. Proportion meta-analysis (random-effect model) and beta-regression were conducted to assess the impact of platinum agents on response rate as well as significance of other variables. In the beta-regression model response rate was a dependent variable, while platinum agents (yes or no), used non-platinum drugs and method of response assessment were independent variables. Statistical analysis was dose with meta, metafor and betareg packages of R software.Results we identified 7156 articles and screened them for title and abstract, 157 studies for further analysis. Overall, 6327 patients were included in the analysis, efficacy of non-platinum- and platinum-based therapy was assessed in 113 (n = 5272) and 44 (n = 1055) trials respectively. In meta-proportion random-effect model RR among patients treated with platinum-based and non-platinum chemotherapy RR was 36% (95% CI 30-41; I2 = 62%) and 16% (95% CI 14-19; I2=70%) respectively. For sensitivity analysis various regression models were made with different subsets of the trials and additional variables (including year of the trial, percentage of serous subtype of OC and median of prior therapy lines). Platinum was the strongest predictor of response in every developed model.Conclusion this meta-analysis shows that patients with ‘platinum-resistant’ ovarian carcinoma may derive significant benefit from reintroduction of platinum agents. These results support recent ESMO-ESGO consensus on treatment of recurrent ovarian cancer.Competing Interest StatementDr. Rumyantsev declared research funding of honoraria from AstraZeneca, MSD, Merck, BIOCAD, R-Pharm, Eisai. Dr. Tyulyandina declared research funding of honoraria from Astra Zeneca, Roche, MSD, Biocad, Tekeda, Pfiser, Eisai; Dr. Fedyanin declared no conflict of interest. Dr. Pokataev declared no conflict of interest. Dr. Glazkova declared research funding of honoraria from MSD, Pfizer, Eisai, Novartis, Pfizer. Dr. Tjulandin declared research funding of honoraria from RosPharmTech, AstraZeneca, BioCad, Lilly, Novartis, Roche, MSD, Pierre Fabre, R-Pharm, Abbvie, BMS, ServierFunding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PubMed database queries have been performed with predefined criteria to include all prospective and retrospective full-text articles and abstracts for all years in 01/01/2000-01/07/2019 timeline in English.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors